Diabeloop DBLG1闭环系统在真实环境中显著改善1型糖尿病患者的血糖控制且无严重不良事件:6个月随访
本研究评估Diabeloop DBLG1混合闭环人工胰腺系统在真实世界中对1型糖尿病患者的疗效与安全性。25例患者经过1周导入期后使用商用DBLG1系统6个月,结果显示糖化血红蛋白从基线7.9%降至7.1%(P<0.001),目标范围内时间从53%升至69.7%(P<0.0001),且无严重不良事件报告。
要点
- 目标范围内时间(TIR 70-180 mg/dL)从53%提升至69.7%
- 低血糖时间(<70 mg/dL)从2.4%降至1.3%(P=0.03)
核心结论
- DBLG1系统能在真实世界条件下显著改善1型糖尿病患者的血糖控制,且无严重不良事件。
研究设计与样本
- 前瞻性随访研究,25例1型糖尿病患者经过1周导入期后使用商用DBLG1混合闭环系统,随访6个月。
- 患者平均年龄43岁(SD 13.8,范围25-72岁)。
主要发现
- 基线平均HbA1c为7.9%(SD 0.93,范围5.6-8.5%),6个月时降至7.1%(P<0.001)。
- 基线TIR 70-180 mg/dL为53%(SD 16.4,范围21-85%),6个月时升至69.7%(P<0.0001)。
- TIR<70 mg/dL从2.4%降至1.3%(P=0.03),TIR<54 mg/dL从0.32%降至0.24%(P=0.42)。
- 1例患者在2个月后停止使用系统,研究期间未报告严重不良事件。
关键数值与推荐
- 6个月时平均HbA1c降至7.1%[54 mmol/mol](P<0.001)。
- 6个月时TIR 70-180 mg/dL升至69.7%(P<0.0001)。
- TIR<70 mg/dL降至1.3%(P=0.03),TIR<54 mg/dL降至0.24%(P=0.42)。
临床怎么用
- 在真实世界临床实践中,DBLG1混合闭环系统可用于1型糖尿病患者以改善血糖控制。
- 使用该系统需关注HbA1c和TIR的改善,同时监测低血糖事件。
局限性
- 样本量较小(25例),随访时间6个月,1例患者退出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyze safety and efficacy of the Diabeloop Generation 1 (DBLG1) hybrid closed-loop artificial pancreas system in patients with type 1 diabetes in real-world conditions. RESEARCH DESIGN AND METHODS: After a 1-week run-in period with their usual pump, 25 patients were provided the commercial DBLG1 system. The results are presented on time in range (TIR) and HbA1c over 6 months. RESULTS: The mean (SD; range) age of patients was 43 (13.8; 25-72) years. At baseline, the mean HbA1c and TIR 70-180 mg/dL were, respectively, 7.9% (0.93; 5.6-8.5%) [63 mmol/mol (10; 38-69 mmol/mol)] and 53% (16.4; 21-85%). One patient stopped using the system after 2 months. At 6 months, the mean HbA1c decreased to 7.1% [54 mmol/mol] (P < 0.001) and TIR 70-180 mg/dL increased to 69.7% (P < 0.0001). TIR <70 mg/dL decreased from 2.4 to 1.3% (P = 0.03), and TIR <54 mg/dL decreased from 0.32 to 0.24% (P = 0.42). No serious adverse event was reported during the study. CONCLUSIONS: The ability of the DBLG1 system to significantly improve glycemic control in real-world conditions, without serious adverse events, was confirmed in this follow-up study.
引用
- Amadou C, Franc S, Benhamou PY, et al. Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up. Diabetes Care. 2021. PMID: 33431420. doi:10.2337/dc20-1809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。